CD79A and infection: All vaccinated subjects, irrespective of their prior infection status, developed anti‐spike IgG and IgA antibodies at 1 week after the second dose of vaccine, with only one slow seroconvertor with detectable antibodies only after 6 weeks post‐second dose.